Cargando…

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease

Background. Lipoprotein(a) (Lp(a)) is a genetic risk factor of atherosclerotic cardiovascular diseases (ASCVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is related to vascular inflammation and detected in atherosclerotic plaques. A temporary increase in the circulating concentration of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afanasieva, Olga I., Tyurina, Alexandra V., Ezhov, Marat V., Razova, Oxana A., Klesareva, Elena A., Pokrovsky, Sergei N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594435/ https://www.ncbi.nlm.nih.gov/pubmed/37873789 http://dx.doi.org/10.3390/diseases11040145

Ejemplares similares

Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease
por: Afanasieva, Olga I., et al.
Publicado: (2022)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Low Molecular Weight Apolipoprotein(a) Phenotype Rather Than Lipoprotein(a) Is Associated With Coronary Atherosclerosis and Myocardial Infarction
por: Afanasieva, Olga I., et al.
Publicado: (2022)

The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis
por: Afanasieva, Olga I., et al.
Publicado: (2021)

Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis
por: Chubykina, Uliana V., et al.
Publicado: (2022)

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
por: Filatova, Anastasiia Yu., et al.
Publicado: (2023)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
por: Tmoyan, Narek A., et al.
Publicado: (2021)

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis
por: Burdeynaya, Anna L., et al.
Publicado: (2023)

Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels
por: Ezhov, Marat, et al.
Publicado: (2019)

Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries
por: Ezhov, Marat V., et al.
Publicado: (2021)

Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
por: Ilina, Larisa N., et al.
Publicado: (2022)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases
por: Ezhov, Marat V., et al.
Publicado: (2021)

Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer’s disease
por: Fitz, Nicholas F., et al.
Publicado: (2021)

Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice
por: Wu, Hongyan, et al.
Publicado: (2021)

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
por: Ezhov, Marat V., et al.
Publicado: (2023)

Lipoprotein(a) Interactions With Low‐Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)
por: Afshar, Mehdi, et al.
Publicado: (2016)

High-Density Lipoprotein Changes in Alzheimer’s Disease Are APOE Genotype-Specific
por: Hong, Brian V., et al.
Publicado: (2022)

Potential role of ATM in hepatocyte endocytosis of ApoE-deficient, ApoB48-containing lipoprotein in ApoE-deficient mice
por: WU, JIANHUA, et al.
Publicado: (2014)

Biosynthesis of lipoprotein: location of nascent apoAI and apoB in the rough endoplasmic reticulum of chicken hepatocytes
Publicado: (1992)

Polymorphism of Apo lipoprotein E gene and the risk of multiple sclerosis
por: Sadeghi, Hamid Mirmohammad, et al.
Publicado: (2011)

Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism
por: Gazzaruso, Carmine, et al.
Publicado: (2002)

The association between fasting serum insulin, apo-lipoproteins level, and severity of coronary artery involvement in non-diabetic patients
por: Golshahi, Jafar, et al.
Publicado: (2014)

Nonfasting Apo-lipoprotein B and Triglyceride levels as a predictor of coronary heart disease in Type II diabetic patients
por: Nayyer-uz-Zaman,, et al.
Publicado: (2018)

A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate
por: Kodera, Hitoshi, et al.
Publicado: (2017)

Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD
por: Baroni, Marco G, et al.
Publicado: (2003)

Elevated lipoprotein(a) as a predictor for coronary events in older men
por: Bartoli-Leonard, Francesca, et al.
Publicado: (2022)

SAA is Found on ApoB-Containing Lipoproteins in Obese Diabetic Humans
por: Jahangiri, Anisa, et al.
Publicado: (2013)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations
por: Yang, Mingxin, et al.
Publicado: (2020)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Comparison of 5-Year Outcomes for Patients With Coronary Artery Disease in Groups With and Without Revascularization With Different Results of Stress Echocardiography
por: Zagatina, Angela, et al.
Publicado: (2013)

Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins
por: Wang, Liyun, et al.
Publicado: (2014)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

ApoM binds endotoxin contributing to neutralization and clearance by High Density Lipoprotein
por: Mousa, Hanaa, et al.
Publicado: (2023)

Impact of premature coronary artery disease on adverse event risk following first percutaneous coronary intervention
por: Pinxterhuis, Tineke H., et al.
Publicado: (2023)

Low-density lipoprotein receptor gene mutation at Exon 2 and 4 in premature coronary artery disease in our population
por: Rehman, Saqibah, et al.
Publicado: (2019)

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease
por: Sorokin, Alexander V., et al.
Publicado: (2023)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
por: Chen, Zhihao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aah81563eb2nidp6r17n8ahbmv